# Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

> **NCT01304498** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 600 (actual)

## Conditions studied

- Human Papillomavirus

## Interventions

- **BIOLOGICAL:** V503
- **BIOLOGICAL:** GARDASIL

## Key facts

- **NCT ID:** NCT01304498
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-23
- **Primary completion:** 2011-12-20
- **Final completion:** 2011-12-20
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01304498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01304498, "Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01304498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*